Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - ...
Gimv [BE0003699130/GIMB]   
[02/12/2020]

Gimv : Gimv sells Itho Daalderop-Climate for Life - Dutch market leader in integrated sustainable solutions for energy-neutral living in the Benelux - to Parcom

Antwerp BE / Schiedam NL, 2 December 2020, 7:30 CET EMBARGO Gimv sells Itho DaalderopClimate for Life Dutch market leader in integrated sustainable solutions for energyneutral living in the Benelux to Parcom Producer Itho Daalderop and service provider Klimaatgarant today announce an important step in their development. Gimv will sell its majority... See more
 
Gimv [BE0003699130/GIMB]   
[30/11/2020]

Gimv : Gimv is founding investor of Kinaset Therapeutics in a USD 40m Series A round – funds used to develop novel therapeutics for respiratory diseases

Antwerp BE / Medfield, MA US, 30 November 2020, 8:00 AM CET Gimv is founding investor of Kinaset Therapeutics in a USD 40m series A round – funds used to develop novel therapeutics for respiratory diseases Gimv invests in Kinaset Therapeutics alongside 5AM Ventures and Atlas Venture in a USD 40m Series A round to support the clinical development of... See more
 
Gimv [BE0003699130/GIMB]   
[19/11/2020]

Gimv : Gimv invests in SynOx Therapeutics which raises EUR 37 million to develop emactuzumab for treatment of tenosynovial giant cell tumors

Antwerp/Dublin, 19 November 2020, 7:30 AM CET Gimv invests in SynOx Therapeutics which raises EUR 37 million to develop emactuzumab for treatment of tenosynovial giant cell tumors Gimv is investing in newly formed SynOx Therapeutics through a Series A round of EUR 37 million along with HealthCap, Medicxi and Forbion. SynOx will continue the development of... See more
 
Gimv [BE0003699130/GIMB]   
[19/11/2020]

Gimv : Strong results on the back of a resilient portfolio

Antwerp, 19 November 2020, 7:00 CET Strong results on the back of a resilient portfolio CEO Koen Dejonckheere: Following the significant negative correction at the end of the previous financial year due to the pandemic crisis, Gimv achieved a 12% return on its portfolio in the first half of the 202021 financial year. This reflects not only the... See more
 
Gimv [BE0003699130/GIMB]   
[22/10/2020]

Gimv : Gimv and founder sell Eurocept Homecare - active in ’Hospital-at-home‘ services and complex wound care - to Mediq

Antwerp BE / The Hague NL / Houten NL, 22 October 2020, 17u45 CET Gimv and founder sell Eurocept Homecare active in ’Hospitalathome‘ services and complex wound care to Mediq Eurocept today announces an important step in its growth. Founder Mike van Woensel and Gimv sell their stake in Eurocept Homecare to Mediq. Mediq is part of Mediq Group, a leading... See more